| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis, Inclusion Body | 34 | 2023 | 145 | 6.130 |
Why?
|
| Muscular Diseases | 23 | 2024 | 554 | 5.210 |
Why?
|
| Myositis | 30 | 2024 | 276 | 4.770 |
Why?
|
| Dermatomyositis | 28 | 2023 | 266 | 4.140 |
Why?
|
| Peripheral Nervous System Diseases | 17 | 2023 | 716 | 2.900 |
Why?
|
| Guillain-Barre Syndrome | 10 | 2023 | 127 | 2.370 |
Why?
|
| Neuromuscular Diseases | 10 | 2021 | 261 | 2.220 |
Why?
|
| Polymyositis | 18 | 2023 | 77 | 2.200 |
Why?
|
| Myasthenia Gravis | 12 | 2022 | 217 | 2.030 |
Why?
|
| Muscle, Skeletal | 52 | 2022 | 4981 | 1.880 |
Why?
|
| Muscle Weakness | 15 | 2019 | 415 | 1.770 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 7 | 2022 | 62 | 1.760 |
Why?
|
| Muscular Dystrophies | 16 | 2014 | 393 | 1.680 |
Why?
|
| Electrodiagnosis | 9 | 2019 | 149 | 1.400 |
Why?
|
| Immunoglobulins, Intravenous | 14 | 2024 | 669 | 1.260 |
Why?
|
| Polyneuropathies | 8 | 2019 | 139 | 1.110 |
Why?
|
| Muscle Proteins | 11 | 2012 | 1165 | 1.010 |
Why?
|
| Myotonic Dystrophy | 4 | 2023 | 80 | 0.950 |
Why?
|
| cis-trans-Isomerases | 1 | 2024 | 45 | 0.940 |
Why?
|
| Retinal Dystrophies | 1 | 2024 | 65 | 0.890 |
Why?
|
| Fasciitis | 2 | 2016 | 67 | 0.880 |
Why?
|
| Immunologic Factors | 5 | 2021 | 1597 | 0.850 |
Why?
|
| Electroretinography | 1 | 2024 | 524 | 0.800 |
Why?
|
| Glycogen Storage Disease Type II | 4 | 2016 | 43 | 0.800 |
Why?
|
| Immunosuppressive Agents | 18 | 2020 | 4209 | 0.760 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 4 | 2013 | 37 | 0.750 |
Why?
|
| Scapula | 2 | 2013 | 175 | 0.740 |
Why?
|
| Neurology | 4 | 2020 | 786 | 0.730 |
Why?
|
| Biopsy | 31 | 2023 | 6808 | 0.730 |
Why?
|
| Leg | 5 | 2020 | 1088 | 0.710 |
Why?
|
| Neural Conduction | 14 | 2015 | 443 | 0.710 |
Why?
|
| Fibric Acids | 1 | 2019 | 27 | 0.680 |
Why?
|
| Multiple Acyl Coenzyme A Dehydrogenase Deficiency | 1 | 2019 | 6 | 0.660 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 106 | 0.650 |
Why?
|
| Autoimmune Diseases | 5 | 2024 | 2257 | 0.620 |
Why?
|
| Charcot-Marie-Tooth Disease | 3 | 2021 | 102 | 0.620 |
Why?
|
| Interferon Type I | 5 | 2020 | 569 | 0.610 |
Why?
|
| Prednisone | 10 | 2021 | 1567 | 0.600 |
Why?
|
| Humans | 253 | 2024 | 768393 | 0.590 |
Why?
|
| Edema | 3 | 2020 | 766 | 0.580 |
Why?
|
| Calpain | 3 | 2009 | 147 | 0.560 |
Why?
|
| Amyloidosis | 2 | 2020 | 879 | 0.550 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 4 | 2023 | 48 | 0.540 |
Why?
|
| Stiff-Person Syndrome | 2 | 2012 | 31 | 0.520 |
Why?
|
| Creatine Kinase | 11 | 2019 | 685 | 0.520 |
Why?
|
| Boronic Acids | 3 | 2009 | 915 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3252 | 0.490 |
Why?
|
| Authorship | 1 | 2018 | 289 | 0.480 |
Why?
|
| Electromyography | 11 | 2019 | 1402 | 0.480 |
Why?
|
| Visual Acuity | 1 | 2024 | 2714 | 0.460 |
Why?
|
| Myotonia | 5 | 2014 | 18 | 0.450 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2013 | 197 | 0.440 |
Why?
|
| Muscle Strength | 6 | 2021 | 641 | 0.440 |
Why?
|
| Pyrazines | 3 | 2009 | 1206 | 0.440 |
Why?
|
| Paresthesia | 2 | 2013 | 160 | 0.440 |
Why?
|
| Disease Management | 3 | 2024 | 2537 | 0.420 |
Why?
|
| Coffee | 1 | 2017 | 598 | 0.420 |
Why?
|
| Caffeine | 1 | 2017 | 702 | 0.420 |
Why?
|
| Demyelinating Diseases | 4 | 2004 | 358 | 0.420 |
Why?
|
| Middle Aged | 112 | 2024 | 223491 | 0.420 |
Why?
|
| Antibodies | 6 | 2009 | 2425 | 0.410 |
Why?
|
| Muscle Fibers, Skeletal | 5 | 2009 | 552 | 0.410 |
Why?
|
| Receptors, Cholinergic | 3 | 2022 | 244 | 0.410 |
Why?
|
| Electrophysiology | 4 | 2012 | 1266 | 0.410 |
Why?
|
| Eosinophilia | 2 | 2008 | 556 | 0.400 |
Why?
|
| Enzyme Inhibitors | 2 | 2020 | 3722 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1890 | 0.400 |
Why?
|
| Sural Nerve | 6 | 2004 | 105 | 0.380 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 2 | 2020 | 24 | 0.380 |
Why?
|
| Adult | 107 | 2024 | 223640 | 0.370 |
Why?
|
| Autoantibodies | 6 | 2024 | 2126 | 0.370 |
Why?
|
| Pain | 5 | 2020 | 5103 | 0.370 |
Why?
|
| Male | 134 | 2024 | 364902 | 0.360 |
Why?
|
| Publishing | 1 | 2018 | 836 | 0.360 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 243 | 0.360 |
Why?
|
| Female | 130 | 2024 | 397089 | 0.350 |
Why?
|
| Thymectomy | 4 | 2020 | 200 | 0.350 |
Why?
|
| Gangliosides | 1 | 2010 | 132 | 0.340 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1794 | 0.340 |
Why?
|
| Spinal Cord Diseases | 1 | 2012 | 293 | 0.330 |
Why?
|
| Myofibrils | 3 | 2014 | 143 | 0.330 |
Why?
|
| Drainage | 2 | 2013 | 1184 | 0.320 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 355 | 0.320 |
Why?
|
| Membrane Proteins | 6 | 2011 | 7880 | 0.310 |
Why?
|
| Time | 2 | 2021 | 546 | 0.310 |
Why?
|
| Exercise Tolerance | 3 | 2003 | 848 | 0.310 |
Why?
|
| Enzyme Therapy | 1 | 2008 | 8 | 0.310 |
Why?
|
| alpha-Glucosidases | 1 | 2008 | 46 | 0.300 |
Why?
|
| Ganglia, Spinal | 1 | 2010 | 530 | 0.300 |
Why?
|
| Aged | 82 | 2022 | 171562 | 0.290 |
Why?
|
| Muscles | 10 | 2016 | 1582 | 0.290 |
Why?
|
| Myostatin | 1 | 2009 | 129 | 0.290 |
Why?
|
| Interferon-beta | 3 | 2007 | 349 | 0.290 |
Why?
|
| Diagnosis, Differential | 17 | 2018 | 13020 | 0.290 |
Why?
|
| Vacuoles | 2 | 2013 | 224 | 0.280 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2013 | 1039 | 0.280 |
Why?
|
| Nervous System Diseases | 4 | 2021 | 1664 | 0.280 |
Why?
|
| Muscle Contraction | 3 | 2022 | 1208 | 0.280 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 59686 | 0.280 |
Why?
|
| Persian Gulf Syndrome | 2 | 1997 | 48 | 0.270 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 250 | 0.270 |
Why?
|
| Interferon-alpha | 4 | 2013 | 910 | 0.270 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 2 | 1996 | 22 | 0.260 |
Why?
|
| Immunotherapy | 6 | 2024 | 4738 | 0.260 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2009 | 1473 | 0.260 |
Why?
|
| Sensory Receptor Cells | 1 | 2010 | 508 | 0.260 |
Why?
|
| Carnitine | 4 | 2001 | 254 | 0.260 |
Why?
|
| Genetic Testing | 3 | 2016 | 3587 | 0.250 |
Why?
|
| Disease Progression | 9 | 2023 | 13646 | 0.250 |
Why?
|
| Necrosis | 3 | 2024 | 1621 | 0.250 |
Why?
|
| Double-Blind Method | 15 | 2023 | 12456 | 0.250 |
Why?
|
| Toxins, Biological | 1 | 2005 | 59 | 0.250 |
Why?
|
| Immune System | 1 | 2010 | 801 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2010 | 1628 | 0.230 |
Why?
|
| Mononeuropathies | 1 | 2004 | 13 | 0.230 |
Why?
|
| Societies, Medical | 6 | 2017 | 3960 | 0.230 |
Why?
|
| Plasma Cells | 3 | 2010 | 599 | 0.230 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2003 | 8 | 0.230 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2024 | 64 | 0.230 |
Why?
|
| Greenhouse Effect | 1 | 2004 | 31 | 0.230 |
Why?
|
| Immunization, Passive | 2 | 2022 | 619 | 0.220 |
Why?
|
| Frameshift Mutation | 1 | 2005 | 393 | 0.210 |
Why?
|
| Sucrose | 1 | 2003 | 159 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 9261 | 0.210 |
Why?
|
| Motor Neuron Disease | 5 | 2013 | 98 | 0.210 |
Why?
|
| Cyclin D1 | 1 | 2005 | 453 | 0.210 |
Why?
|
| Intermittent Claudication | 3 | 2001 | 305 | 0.210 |
Why?
|
| Peripheral Nerves | 4 | 2021 | 492 | 0.210 |
Why?
|
| Receptors, CCR5 | 1 | 2005 | 491 | 0.210 |
Why?
|
| Rheumatology | 3 | 2017 | 619 | 0.210 |
Why?
|
| Dyspnea | 1 | 2011 | 1351 | 0.210 |
Why?
|
| Medicine | 1 | 2011 | 948 | 0.210 |
Why?
|
| Myotonic Disorders | 2 | 2014 | 7 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 2 | 2022 | 839 | 0.210 |
Why?
|
| Immunohistochemistry | 13 | 2014 | 11120 | 0.210 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2022 | 21 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2017 | 1813 | 0.200 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 684 | 0.200 |
Why?
|
| Median Nerve | 4 | 2019 | 133 | 0.200 |
Why?
|
| Neuromuscular Junction Diseases | 3 | 2015 | 14 | 0.200 |
Why?
|
| Treatment Outcome | 25 | 2023 | 65379 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
| Hypesthesia | 2 | 2018 | 106 | 0.200 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2001 | 32 | 0.190 |
Why?
|
| Industry | 1 | 2004 | 365 | 0.190 |
Why?
|
| Prealbumin | 1 | 2004 | 259 | 0.190 |
Why?
|
| Lectins, C-Type | 3 | 2019 | 591 | 0.190 |
Why?
|
| Inflammation | 3 | 2018 | 10863 | 0.190 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5192 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2010 | 3794 | 0.190 |
Why?
|
| Conservation of Natural Resources | 1 | 2004 | 209 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 2 | 2008 | 2709 | 0.190 |
Why?
|
| Technology | 1 | 2004 | 296 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 7453 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2017 | 187 | 0.190 |
Why?
|
| Dystrophin | 4 | 2006 | 284 | 0.190 |
Why?
|
| Consensus | 7 | 2023 | 3212 | 0.190 |
Why?
|
| Ganglia, Sensory | 1 | 2020 | 19 | 0.180 |
Why?
|
| Ganglia, Autonomic | 1 | 2021 | 43 | 0.180 |
Why?
|
| Graft vs Host Disease | 2 | 2009 | 3044 | 0.180 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 1602 | 0.180 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 4120 | 0.180 |
Why?
|
| Muscular Atrophy | 2 | 2014 | 335 | 0.180 |
Why?
|
| Mutation | 16 | 2016 | 30228 | 0.180 |
Why?
|
| Glucan 1,4-alpha-Glucosidase | 1 | 2000 | 8 | 0.180 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 43 | 0.180 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2020 | 17 | 0.170 |
Why?
|
| Antibodies, Antinuclear | 1 | 2001 | 343 | 0.170 |
Why?
|
| Meningitis | 1 | 2001 | 219 | 0.170 |
Why?
|
| Glycogen Storage Disease | 1 | 2000 | 41 | 0.170 |
Why?
|
| Severity of Illness Index | 8 | 2019 | 15939 | 0.170 |
Why?
|
| Vasospasm, Intracranial | 2 | 2013 | 214 | 0.170 |
Why?
|
| Agrin | 1 | 2020 | 75 | 0.170 |
Why?
|
| Receptors, GABA-A | 3 | 1999 | 625 | 0.170 |
Why?
|
| Receptors, Nicotinic | 2 | 2020 | 494 | 0.170 |
Why?
|
| Models, Economic | 1 | 2004 | 718 | 0.170 |
Why?
|
| Sulfhydryl Reagents | 1 | 1999 | 29 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 420 | 0.160 |
Why?
|
| Cytokines | 5 | 2017 | 7445 | 0.160 |
Why?
|
| Myopathies, Structural, Congenital | 3 | 2016 | 104 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2019 | 114 | 0.160 |
Why?
|
| Dependovirus | 1 | 2024 | 721 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2020 | 387 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 233 | 0.160 |
Why?
|
| Adolescent | 35 | 2024 | 89184 | 0.160 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2019 | 304 | 0.160 |
Why?
|
| Macrolides | 1 | 2020 | 205 | 0.160 |
Why?
|
| Self Administration | 1 | 2020 | 388 | 0.160 |
Why?
|
| Riboflavin | 1 | 2019 | 107 | 0.160 |
Why?
|
| Receptors, Immunologic | 3 | 2019 | 1416 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 275 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 241 | 0.160 |
Why?
|
| Italy | 7 | 2023 | 854 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2022 | 36849 | 0.150 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2018 | 21 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2005 | 3617 | 0.150 |
Why?
|
| House Calls | 1 | 2020 | 171 | 0.150 |
Why?
|
| Alanine | 1 | 2020 | 613 | 0.150 |
Why?
|
| Exercise Test | 4 | 2014 | 2186 | 0.150 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 612 | 0.150 |
Why?
|
| Environment | 1 | 2004 | 1124 | 0.150 |
Why?
|
| Neurologic Examination | 5 | 2013 | 916 | 0.150 |
Why?
|
| MEDLINE | 1 | 2017 | 119 | 0.150 |
Why?
|
| Scleroderma, Systemic | 1 | 2001 | 349 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1094 | 0.140 |
Why?
|
| Retrospective Studies | 30 | 2024 | 81801 | 0.140 |
Why?
|
| Visual Fields | 1 | 2024 | 1067 | 0.140 |
Why?
|
| Asymptomatic Infections | 1 | 2018 | 135 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 344 | 0.140 |
Why?
|
| Diverticulitis, Colonic | 1 | 2018 | 139 | 0.140 |
Why?
|
| Brachial Plexus | 2 | 2001 | 173 | 0.140 |
Why?
|
| Twins | 1 | 1998 | 340 | 0.140 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 299 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2247 | 0.140 |
Why?
|
| Autoantigens | 4 | 2013 | 891 | 0.140 |
Why?
|
| Child | 28 | 2024 | 80891 | 0.140 |
Why?
|
| Inclusion Bodies | 2 | 1995 | 279 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2012 | 9510 | 0.130 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1998 | 155 | 0.130 |
Why?
|
| Vaccination | 2 | 2023 | 3431 | 0.130 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2016 | 24 | 0.130 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2015 | 8 | 0.130 |
Why?
|
| Upper Extremity | 2 | 2019 | 684 | 0.130 |
Why?
|
| Neurons | 4 | 2013 | 9513 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.130 |
Why?
|
| Sarcoplasmic Reticulum | 3 | 2014 | 164 | 0.130 |
Why?
|
| Young Adult | 21 | 2024 | 60049 | 0.130 |
Why?
|
| Colonoscopy | 3 | 2020 | 1412 | 0.130 |
Why?
|
| Hydroxyethylrutoside | 1 | 2015 | 4 | 0.130 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 81 | 0.130 |
Why?
|
| Diosmin | 1 | 2015 | 6 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2021 | 871 | 0.130 |
Why?
|
| Hemorrhoids | 1 | 2015 | 19 | 0.120 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1995 | 49 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2011 | 4848 | 0.120 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 48 | 0.120 |
Why?
|
| Neurosciences | 1 | 2020 | 385 | 0.120 |
Why?
|
| Hesperidin | 1 | 2015 | 19 | 0.120 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 162 | 0.120 |
Why?
|
| Paralyses, Familial Periodic | 1 | 2014 | 13 | 0.120 |
Why?
|
| Pharyngeal Muscles | 1 | 1995 | 81 | 0.120 |
Why?
|
| Chloride Channels | 2 | 2013 | 222 | 0.120 |
Why?
|
| Autoimmunity | 2 | 2013 | 1360 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 1883 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2024 | 3413 | 0.120 |
Why?
|
| Viral Vaccines | 1 | 2020 | 596 | 0.120 |
Why?
|
| Fatigue | 3 | 2018 | 1555 | 0.120 |
Why?
|
| Channelopathies | 1 | 2014 | 32 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 9433 | 0.120 |
Why?
|
| Alleles | 2 | 2005 | 6892 | 0.120 |
Why?
|
| Smad2 Protein | 1 | 2014 | 144 | 0.120 |
Why?
|
| Smad3 Protein | 1 | 2014 | 166 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1996 | 419 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2925 | 0.110 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 250 | 0.110 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 123 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1285 | 0.110 |
Why?
|
| Antiviral Agents | 3 | 2020 | 3064 | 0.110 |
Why?
|
| Picolines | 1 | 2013 | 9 | 0.110 |
Why?
|
| Axons | 1 | 2002 | 1678 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 98 | 0.110 |
Why?
|
| Colorectal Surgery | 2 | 2012 | 122 | 0.110 |
Why?
|
| Age of Onset | 6 | 2013 | 3345 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2004 | 2240 | 0.110 |
Why?
|
| Colonic Polyps | 1 | 2018 | 557 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2001 | 1813 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 1118 | 0.110 |
Why?
|
| Facial Transplantation | 1 | 2016 | 222 | 0.110 |
Why?
|
| Retina | 1 | 2024 | 2661 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 239 | 0.110 |
Why?
|
| Citrates | 1 | 2013 | 134 | 0.110 |
Why?
|
| Lower Extremity | 2 | 2019 | 1218 | 0.110 |
Why?
|
| Observer Variation | 1 | 2019 | 2623 | 0.110 |
Why?
|
| Mycophenolic Acid | 2 | 2006 | 350 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 4414 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2021 | 1080 | 0.100 |
Why?
|
| Mutation, Missense | 2 | 2020 | 2593 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2014 | 288 | 0.100 |
Why?
|
| Shoulder Pain | 1 | 2014 | 152 | 0.100 |
Why?
|
| Anastomotic Leak | 1 | 2014 | 171 | 0.100 |
Why?
|
| Muscle Cells | 2 | 2012 | 195 | 0.100 |
Why?
|
| Celiac Disease | 1 | 2020 | 820 | 0.100 |
Why?
|
| Cathartics | 1 | 2013 | 129 | 0.100 |
Why?
|
| Dynamin II | 1 | 2012 | 35 | 0.100 |
Why?
|
| Insurance Claim Reporting | 1 | 2013 | 166 | 0.100 |
Why?
|
| Amides | 2 | 2008 | 452 | 0.100 |
Why?
|
| Chromosome Mapping | 4 | 2011 | 4622 | 0.100 |
Why?
|
| Cell Nucleus | 3 | 2014 | 2886 | 0.100 |
Why?
|
| Quadriceps Muscle | 1 | 2013 | 157 | 0.100 |
Why?
|
| Stents | 4 | 2014 | 3201 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2013 | 164 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5800 | 0.100 |
Why?
|
| Medical Records | 3 | 2013 | 1412 | 0.100 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 359 | 0.100 |
Why?
|
| Antineoplastic Agents | 5 | 2009 | 13697 | 0.100 |
Why?
|
| Research | 1 | 2020 | 1981 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 8753 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 2544 | 0.090 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2015 | 330 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 2276 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 1995 | 405 | 0.090 |
Why?
|
| Organ Size | 2 | 2014 | 2268 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 598 | 0.090 |
Why?
|
| Dystroglycans | 1 | 2011 | 62 | 0.090 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 8051 | 0.090 |
Why?
|
| Medicare Part B | 1 | 2012 | 117 | 0.090 |
Why?
|
| Phenotype | 6 | 2019 | 16721 | 0.090 |
Why?
|
| Membrane Glycoproteins | 4 | 2007 | 3712 | 0.090 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2011 | 38 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1274 | 0.090 |
Why?
|
| Rectal Neoplasms | 2 | 2008 | 1188 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 1643 | 0.090 |
Why?
|
| Genes, Recessive | 1 | 2013 | 625 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2013 | 731 | 0.090 |
Why?
|
| Physical Examination | 2 | 2012 | 1262 | 0.090 |
Why?
|
| Biomedical Technology | 1 | 2012 | 210 | 0.090 |
Why?
|
| Peroneal Nerve | 3 | 2000 | 80 | 0.090 |
Why?
|
| Myelin Proteins | 1 | 2011 | 212 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2013 | 658 | 0.090 |
Why?
|
| Air Pollution | 1 | 2004 | 2363 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2016 | 2168 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 648 | 0.080 |
Why?
|
| Glycogen | 2 | 2003 | 252 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2014 | 8326 | 0.080 |
Why?
|
| Microscopy, Electron | 2 | 2006 | 2559 | 0.080 |
Why?
|
| Animals | 19 | 2023 | 169337 | 0.080 |
Why?
|
| Sarcomeres | 2 | 2009 | 380 | 0.080 |
Why?
|
| Myopathies, Nemaline | 1 | 2010 | 73 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6971 | 0.080 |
Why?
|
| Exanthema | 2 | 2016 | 503 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2010 | 4785 | 0.080 |
Why?
|
| Hand Strength | 1 | 2012 | 466 | 0.080 |
Why?
|
| X Chromosome | 1 | 1993 | 819 | 0.080 |
Why?
|
| Lysine Carboxypeptidase | 1 | 1989 | 2 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2013 | 572 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2012 | 856 | 0.080 |
Why?
|
| Myelitis, Transverse | 2 | 2013 | 40 | 0.080 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2009 | 71 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 1943 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 325 | 0.080 |
Why?
|
| Microdissection | 4 | 2010 | 151 | 0.080 |
Why?
|
| Single-Blind Method | 3 | 2020 | 1585 | 0.080 |
Why?
|
| Diverticulitis | 1 | 2011 | 187 | 0.080 |
Why?
|
| Skin | 1 | 2023 | 4499 | 0.080 |
Why?
|
| Proteomics | 4 | 2010 | 3906 | 0.080 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2007 | 316 | 0.080 |
Why?
|
| Carboxypeptidases | 1 | 1989 | 121 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 581 | 0.080 |
Why?
|
| Desmin | 3 | 2012 | 99 | 0.080 |
Why?
|
| Thymus Neoplasms | 2 | 2022 | 277 | 0.080 |
Why?
|
| Placebos | 2 | 2013 | 1668 | 0.080 |
Why?
|
| Syndecan-1 | 2 | 2007 | 163 | 0.080 |
Why?
|
| Ubiquitins | 1 | 2010 | 366 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 450 | 0.080 |
Why?
|
| Aminopeptidases | 1 | 1989 | 114 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 3857 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2019 | 11668 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 611 | 0.080 |
Why?
|
| United States | 14 | 2023 | 73150 | 0.080 |
Why?
|
| Gene Deletion | 1 | 1996 | 2673 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2016 | 4031 | 0.070 |
Why?
|
| Child, Preschool | 12 | 2021 | 42650 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2013 | 709 | 0.070 |
Why?
|
| Voice | 1 | 2011 | 268 | 0.070 |
Why?
|
| Leukocytes | 2 | 2013 | 2030 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2014 | 5713 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 755 | 0.070 |
Why?
|
| Telephone | 1 | 2011 | 630 | 0.070 |
Why?
|
| Enzymes | 1 | 2009 | 254 | 0.070 |
Why?
|
| Glycosylation | 1 | 2011 | 1100 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1195 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 1993 | 2342 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 465 | 0.070 |
Why?
|
| GTP-Binding Proteins | 3 | 2007 | 947 | 0.070 |
Why?
|
| GTP Phosphohydrolases | 1 | 2011 | 525 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 584 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 1377 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1989 | 326 | 0.070 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2007 | 44 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 4570 | 0.070 |
Why?
|
| MicroRNAs | 3 | 2014 | 3804 | 0.070 |
Why?
|
| Dendritic Cells | 3 | 2010 | 2749 | 0.070 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2007 | 58 | 0.070 |
Why?
|
| Technetium | 1 | 2007 | 326 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 2010 | 855 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 9614 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 1083 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2012 | 942 | 0.070 |
Why?
|
| Europe | 3 | 2017 | 3439 | 0.070 |
Why?
|
| Health Resources | 1 | 2012 | 950 | 0.070 |
Why?
|
| Syndecans | 1 | 2005 | 75 | 0.070 |
Why?
|
| Motor Neurons | 5 | 2003 | 872 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2018 | 54920 | 0.060 |
Why?
|
| Immunization | 1 | 2010 | 1219 | 0.060 |
Why?
|
| Sicily | 1 | 2005 | 10 | 0.060 |
Why?
|
| Biological Assay | 1 | 2009 | 627 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 1065 | 0.060 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2006 | 138 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2005 | 962 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4646 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 752 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 6510 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3438 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2006 | 189 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2007 | 241 | 0.060 |
Why?
|
| Phosphorus Radioisotopes | 3 | 2000 | 100 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2010 | 620 | 0.060 |
Why?
|
| Tramadol | 1 | 2006 | 63 | 0.060 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2006 | 130 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3471 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1762 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2008 | 335 | 0.060 |
Why?
|
| Capillaries | 2 | 2007 | 756 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 977 | 0.060 |
Why?
|
| Antigens, Surface | 2 | 2007 | 1616 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2012 | 12805 | 0.060 |
Why?
|
| Ultrasonography | 3 | 2019 | 6001 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 687 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 780 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2023 | 8731 | 0.060 |
Why?
|
| Blood Vessels | 2 | 2012 | 1110 | 0.060 |
Why?
|
| Steel | 1 | 2004 | 27 | 0.060 |
Why?
|
| Ethylenes | 1 | 2004 | 43 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2004 | 105 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5705 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2007 | 11918 | 0.060 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 14737 | 0.060 |
Why?
|
| Infant | 8 | 2014 | 36510 | 0.060 |
Why?
|
| Sarcolemma | 2 | 2020 | 66 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1376 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2012 | 1161 | 0.060 |
Why?
|
| Glycolysis | 2 | 2009 | 838 | 0.060 |
Why?
|
| Viremia | 2 | 2018 | 725 | 0.060 |
Why?
|
| Paper | 1 | 2004 | 84 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2005 | 167 | 0.060 |
Why?
|
| Cell Movement | 2 | 2013 | 5215 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 1795 | 0.060 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2007 | 547 | 0.050 |
Why?
|
| Anastomosis, Surgical | 3 | 2014 | 993 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2009 | 1575 | 0.050 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2003 | 52 | 0.050 |
Why?
|
| beta-Thalassemia | 2 | 1997 | 236 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 841 | 0.050 |
Why?
|
| Logistic Models | 5 | 2017 | 13323 | 0.050 |
Why?
|
| Neoplasms | 3 | 2003 | 22385 | 0.050 |
Why?
|
| Anesthetics, General | 1 | 2005 | 152 | 0.050 |
Why?
|
| Vinculin | 1 | 2003 | 59 | 0.050 |
Why?
|
| Talin | 1 | 2003 | 47 | 0.050 |
Why?
|
| DNA | 2 | 1996 | 7211 | 0.050 |
Why?
|
| Reference Values | 4 | 2017 | 4941 | 0.050 |
Why?
|
| Apoptosis | 1 | 1999 | 9516 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3486 | 0.050 |
Why?
|
| Anesthetics, Intravenous | 1 | 2006 | 397 | 0.050 |
Why?
|
| Radial Nerve | 3 | 1999 | 44 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2742 | 0.050 |
Why?
|
| Ulnar Nerve | 3 | 1999 | 104 | 0.050 |
Why?
|
| Mice | 12 | 2023 | 82017 | 0.050 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 924 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2005 | 807 | 0.050 |
Why?
|
| Caveolae | 1 | 2022 | 54 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3107 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3236 | 0.050 |
Why?
|
| Brachytherapy | 2 | 2000 | 1226 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 412 | 0.050 |
Why?
|
| Gait Ataxia | 1 | 2001 | 11 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5375 | 0.050 |
Why?
|
| Sorbitol | 1 | 2021 | 61 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2007 | 832 | 0.050 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2003 | 217 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2004 | 252 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8562 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2009 | 2771 | 0.050 |
Why?
|
| Rectum | 2 | 2020 | 902 | 0.050 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 413 | 0.050 |
Why?
|
| Intercalating Agents | 1 | 2001 | 33 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 1004 | 0.050 |
Why?
|
| Hospitalization | 2 | 2018 | 10844 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2008 | 1158 | 0.050 |
Why?
|
| Acetylcarnitine | 1 | 2000 | 9 | 0.050 |
Why?
|
| Baclofen | 1 | 2021 | 120 | 0.050 |
Why?
|
| Arm | 3 | 2018 | 590 | 0.050 |
Why?
|
| Age Factors | 5 | 2012 | 18471 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 2258 | 0.040 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 10267 | 0.040 |
Why?
|
| Acute Disease | 3 | 2018 | 7242 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2005 | 1090 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 8075 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2023 | 450 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2001 | 140 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2006 | 1180 | 0.040 |
Why?
|
| Tibial Nerve | 2 | 1999 | 55 | 0.040 |
Why?
|
| Policy Making | 1 | 2004 | 545 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2007 | 2574 | 0.040 |
Why?
|
| Adenine | 1 | 2006 | 993 | 0.040 |
Why?
|
| Prognosis | 5 | 2010 | 30022 | 0.040 |
Why?
|
| Propofol | 1 | 2006 | 608 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 2 | 1999 | 927 | 0.040 |
Why?
|
| Cell Line | 5 | 2014 | 15597 | 0.040 |
Why?
|
| Dithionitrobenzoic Acid | 1 | 1999 | 22 | 0.040 |
Why?
|
| Pedigree | 3 | 2014 | 4544 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2014 | 1104 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2009 | 9379 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 1469 | 0.040 |
Why?
|
| Action Potentials | 2 | 1997 | 1838 | 0.040 |
Why?
|
| Acetates | 1 | 2001 | 317 | 0.040 |
Why?
|
| Dithiothreitol | 1 | 1999 | 94 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2001 | 1837 | 0.040 |
Why?
|
| Lyme Disease | 1 | 2005 | 630 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 2661 | 0.040 |
Why?
|
| Methotrexate | 2 | 2016 | 1722 | 0.040 |
Why?
|
| Amines | 1 | 2001 | 280 | 0.040 |
Why?
|
| Recurrence | 5 | 2011 | 8506 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2003 | 709 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2015 | 4843 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1082 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2001 | 354 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2012 | 3267 | 0.040 |
Why?
|
| Uncertainty | 1 | 2004 | 759 | 0.040 |
Why?
|
| Mass Spectrometry | 3 | 2013 | 2201 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 319 | 0.040 |
Why?
|
| Radiculopathy | 1 | 2001 | 203 | 0.040 |
Why?
|
| Hallucinations | 1 | 2001 | 375 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2011 | 2059 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2524 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2009 | 1177 | 0.040 |
Why?
|
| Cluster Analysis | 3 | 2012 | 2728 | 0.040 |
Why?
|
| tau Proteins | 1 | 2009 | 2143 | 0.040 |
Why?
|
| Incidence | 7 | 2012 | 21544 | 0.040 |
Why?
|
| Thymoma | 1 | 2020 | 191 | 0.040 |
Why?
|
| Medicaid | 1 | 2012 | 2842 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 2003 | 407 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 240 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2023 | 618 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2012 | 2940 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1989 | 1484 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3541 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2004 | 2170 | 0.040 |
Why?
|
| Integrins | 1 | 2003 | 843 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2007 | 2611 | 0.040 |
Why?
|
| Prostaglandins | 1 | 1999 | 398 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 10776 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4588 | 0.040 |
Why?
|
| Dermis | 1 | 1999 | 203 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 5496 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 1765 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4614 | 0.040 |
Why?
|
| Gene Expression | 4 | 2014 | 7598 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 2475 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2014 | 19022 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2020 | 407 | 0.040 |
Why?
|
| Probability | 2 | 2017 | 2482 | 0.040 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2017 | 43 | 0.040 |
Why?
|
| Neuralgia | 1 | 2004 | 622 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 1013 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2001 | 1143 | 0.040 |
Why?
|
| Piperidines | 1 | 2006 | 1659 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 13576 | 0.030 |
Why?
|
| Distal Myopathies | 1 | 2016 | 18 | 0.030 |
Why?
|
| Up-Regulation | 3 | 2012 | 4142 | 0.030 |
Why?
|
| Vitamin E Deficiency | 1 | 1996 | 30 | 0.030 |
Why?
|
| Spinocerebellar Degenerations | 1 | 1996 | 44 | 0.030 |
Why?
|
| Cohort Studies | 7 | 2014 | 41795 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1998 | 339 | 0.030 |
Why?
|
| Globins | 1 | 1997 | 405 | 0.030 |
Why?
|
| Genomics | 1 | 2012 | 5916 | 0.030 |
Why?
|
| Age Distribution | 2 | 2012 | 2877 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2000 | 2922 | 0.030 |
Why?
|
| Vasculitis | 1 | 2000 | 524 | 0.030 |
Why?
|
| Seasons | 2 | 2012 | 1526 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2016 | 52 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5857 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2001 | 806 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 3458 | 0.030 |
Why?
|
| Goiter, Substernal | 1 | 1995 | 18 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1999 | 1090 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1998 | 484 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4357 | 0.030 |
Why?
|
| Pain Measurement | 3 | 2015 | 3581 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 20224 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1996 | 286 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 1742 | 0.030 |
Why?
|
| Medical Audit | 1 | 2017 | 454 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2016 | 256 | 0.030 |
Why?
|
| Netherlands | 2 | 2014 | 2274 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2000 | 5924 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 414 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 2009 | 997 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2001 | 982 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 628 | 0.030 |
Why?
|
| Iron | 1 | 2004 | 1814 | 0.030 |
Why?
|
| Registries | 2 | 2023 | 8379 | 0.030 |
Why?
|
| Lymphocytosis | 1 | 2016 | 121 | 0.030 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 13423 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 1320 | 0.030 |
Why?
|
| Azathioprine | 1 | 1996 | 354 | 0.030 |
Why?
|
| Vasodilation | 1 | 1999 | 968 | 0.030 |
Why?
|
| Rectal Prolapse | 1 | 2015 | 33 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 1999 | 713 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2008 | 15881 | 0.030 |
Why?
|
| Brain | 3 | 2005 | 27454 | 0.030 |
Why?
|
| Survival Rate | 4 | 2014 | 12870 | 0.030 |
Why?
|
| Mitochondria, Muscle | 1 | 1995 | 172 | 0.030 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2014 | 30 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2012 | 24318 | 0.030 |
Why?
|
| Risk Factors | 6 | 2017 | 74962 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2007 | 2293 | 0.030 |
Why?
|
| Rats | 3 | 2020 | 23835 | 0.030 |
Why?
|
| Research Design | 2 | 2015 | 6210 | 0.030 |
Why?
|
| Weight Loss | 1 | 2006 | 2713 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 605 | 0.030 |
Why?
|
| Arteries | 1 | 1999 | 1126 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5336 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14784 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 38 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4775 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1999 | 905 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5801 | 0.030 |
Why?
|
| Mexiletine | 1 | 2013 | 30 | 0.030 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2016 | 271 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 3620 | 0.030 |
Why?
|
| Atrophy | 1 | 1999 | 1648 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1995 | 475 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 547 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 4859 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 1642 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 6406 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1993 | 71 | 0.030 |
Why?
|
| Manometry | 1 | 1996 | 459 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Extremities | 1 | 1999 | 870 | 0.030 |
Why?
|
| Smad5 Protein | 1 | 2013 | 26 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 1724 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1251 | 0.030 |
Why?
|
| Anal Canal | 1 | 1996 | 376 | 0.030 |
Why?
|
| Heterozygote | 2 | 2006 | 2791 | 0.030 |
Why?
|
| Impotence, Vasculogenic | 1 | 2012 | 13 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2016 | 22296 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 1133 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 2225 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 235 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 2433 | 0.030 |
Why?
|
| Spermatic Cord | 1 | 2012 | 23 | 0.030 |
Why?
|
| Delirium | 1 | 2005 | 1695 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1995 | 489 | 0.030 |
Why?
|
| International Cooperation | 2 | 2013 | 1438 | 0.030 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2012 | 34 | 0.030 |
Why?
|
| Proteins | 1 | 2007 | 6006 | 0.030 |
Why?
|
| Obesity | 2 | 2006 | 13084 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 326 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 1996 | 2002 | 0.030 |
Why?
|
| Linear Models | 1 | 2002 | 5878 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 1998 | 829 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2013 | 205 | 0.030 |
Why?
|
| Neurons, Afferent | 3 | 2001 | 498 | 0.030 |
Why?
|
| Photoplethysmography | 1 | 2012 | 66 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 14154 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15455 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2014 | 564 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 283 | 0.020 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2014 | 179 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2013 | 300 | 0.020 |
Why?
|
| Myosins | 1 | 2013 | 407 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 17626 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 344 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2012 | 163 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1997 | 2226 | 0.020 |
Why?
|
| Time Factors | 4 | 2016 | 40272 | 0.020 |
Why?
|
| Meningococcal Vaccines | 1 | 2012 | 96 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 6856 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 2014 | 409 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2013 | 287 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1991 | 37 | 0.020 |
Why?
|
| Fragile X Syndrome | 1 | 1993 | 116 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 2012 | 146 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2012 | 248 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 368 | 0.020 |
Why?
|
| Surgical Stomas | 1 | 2011 | 45 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2012 | 185 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 17575 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 754 | 0.020 |
Why?
|
| Penis | 1 | 2012 | 210 | 0.020 |
Why?
|
| Clinical Coding | 1 | 2013 | 186 | 0.020 |
Why?
|
| Kinetics | 1 | 1999 | 6333 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 1390 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2012 | 332 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 432 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 1991 | 35 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1999 | 3955 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2014 | 282 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 285 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2014 | 753 | 0.020 |
Why?
|
| Tyrosine | 1 | 1995 | 1428 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 520 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2013 | 2258 | 0.020 |
Why?
|
| Adenoma | 2 | 2018 | 2163 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 640 | 0.020 |
Why?
|
| HIV | 1 | 2018 | 1596 | 0.020 |
Why?
|
| Myocardium | 2 | 2007 | 4788 | 0.020 |
Why?
|
| Life Tables | 1 | 1991 | 368 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 793 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1999 | 1241 | 0.020 |
Why?
|
| Isometric Contraction | 2 | 2005 | 150 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2012 | 341 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2012 | 334 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4291 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2005 | 3985 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 863 | 0.020 |
Why?
|
| Brain Injury, Chronic | 1 | 2011 | 68 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 874 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2015 | 1743 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 11254 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2016 | 657 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 116 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1857 | 0.020 |
Why?
|
| Siblings | 1 | 2014 | 829 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 641 | 0.020 |
Why?
|
| Pelvic Pain | 1 | 2012 | 300 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 326 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2529 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 332 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 1991 | 222 | 0.020 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2009 | 13 | 0.020 |
Why?
|
| Cytosol | 1 | 2013 | 886 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2023 | 26411 | 0.020 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1993 | 260 | 0.020 |
Why?
|
| Congo Red | 1 | 2009 | 48 | 0.020 |
Why?
|
| Psychometrics | 1 | 2019 | 3069 | 0.020 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2010 | 149 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2005 | 10478 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2012 | 916 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 283 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 3048 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2010 | 160 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2017 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2010 | 446 | 0.020 |
Why?
|
| Device Removal | 1 | 2014 | 643 | 0.020 |
Why?
|
| Choristoma | 1 | 2010 | 205 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2015 | 2079 | 0.020 |
Why?
|
| Prevalence | 3 | 2012 | 15872 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 1376 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1996 | 3781 | 0.020 |
Why?
|
| Sufentanil | 1 | 2008 | 42 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 26375 | 0.020 |
Why?
|
| Family Health | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 2491 | 0.020 |
Why?
|
| Actinin | 1 | 2009 | 165 | 0.020 |
Why?
|
| Sex Factors | 2 | 2012 | 10654 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1991 | 602 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 2009 | 164 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 990 | 0.020 |
Why?
|
| Pentosyltransferases | 1 | 2007 | 62 | 0.020 |
Why?
|
| Analgesics | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2012 | 795 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6318 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2011 | 496 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2008 | 117 | 0.020 |
Why?
|
| Germinal Center | 1 | 2010 | 380 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 2176 | 0.020 |
Why?
|
| RecQ Helicases | 1 | 2007 | 53 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1997 | 1552 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 404 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 1126 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 828 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 710 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 1065 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 957 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 960 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 385 | 0.020 |
Why?
|
| Data Mining | 1 | 2012 | 560 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2281 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1999 | 4427 | 0.020 |
Why?
|
| Neurofilament Proteins | 1 | 2009 | 337 | 0.020 |
Why?
|
| Follow-Up Studies | 5 | 2011 | 39407 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 1362 | 0.020 |
Why?
|
| Thiophenes | 1 | 1991 | 569 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 1731 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2011 | 663 | 0.020 |
Why?
|
| Bronchopneumonia | 1 | 2006 | 11 | 0.020 |
Why?
|
| Viral Load | 1 | 2016 | 3398 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 1647 | 0.020 |
Why?
|
| Models, Biological | 2 | 2001 | 9493 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3632 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2007 | 191 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 4250 | 0.020 |
Why?
|
| Anesthetics, Combined | 1 | 2006 | 43 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 1480 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 3529 | 0.020 |
Why?
|
| Reoperation | 2 | 2012 | 4341 | 0.020 |
Why?
|
| Lymphedema | 1 | 2012 | 527 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 1493 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1996 | 2360 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2007 | 420 | 0.020 |
Why?
|
| Lasers | 1 | 2010 | 952 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 12422 | 0.020 |
Why?
|
| G(M1) Ganglioside | 2 | 1997 | 87 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 2489 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21162 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1998 | 6409 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 977 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 767 | 0.010 |
Why?
|
| Analgesia, Epidural | 1 | 2008 | 332 | 0.010 |
Why?
|
| Abdomen | 1 | 1991 | 1136 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 20765 | 0.010 |
Why?
|
| Bupivacaine | 1 | 2008 | 412 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1356 | 0.010 |
Why?
|
| Genome | 1 | 2013 | 1747 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1996 | 2906 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 2005 | 157 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 948 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3617 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5367 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 6993 | 0.010 |
Why?
|
| RNA Interference | 1 | 2013 | 2836 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2008 | 518 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 2407 | 0.010 |
Why?
|
| North America | 1 | 2007 | 1290 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 7145 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 3434 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12092 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 375 | 0.010 |
Why?
|
| Kidney Transplantation | 2 | 2001 | 4300 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2862 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2004 | 642 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1445 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2007 | 2299 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1748 | 0.010 |
Why?
|
| Exons | 2 | 2001 | 2392 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2010 | 1609 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2005 | 370 | 0.010 |
Why?
|
| Internationality | 1 | 2008 | 1008 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2006 | 487 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3707 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2012 | 1459 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2007 | 1967 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2007 | 1393 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 424 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2588 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 4921 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5037 | 0.010 |
Why?
|
| Peptides | 2 | 2009 | 4353 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10588 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 682 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2006 | 1420 | 0.010 |
Why?
|
| Education | 1 | 2004 | 535 | 0.010 |
Why?
|
| Indoles | 1 | 2009 | 1825 | 0.010 |
Why?
|
| Thrombosis | 1 | 2015 | 2955 | 0.010 |
Why?
|
| Data Collection | 1 | 2010 | 3324 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2012 | 1548 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2006 | 1830 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1988 | 1386 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 1748 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 6085 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9343 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9636 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1995 | 6606 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 10377 | 0.010 |
Why?
|
| Beta Particles | 1 | 2000 | 51 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2012 | 9682 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4450 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1993 | 3300 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 1528 | 0.010 |
Why?
|
| Proteome | 1 | 2009 | 1881 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3627 | 0.010 |
Why?
|
| Transfection | 2 | 1998 | 5764 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2000 | 8747 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1379 | 0.010 |
Why?
|
| Introns | 1 | 2001 | 968 | 0.010 |
Why?
|
| Causality | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Isomerism | 1 | 1998 | 198 | 0.010 |
Why?
|
| Energy Intake | 1 | 2006 | 2145 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6541 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 2000 | 4537 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 14481 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6519 | 0.010 |
Why?
|
| Sample Size | 1 | 2001 | 848 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2000 | 459 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2734 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 18048 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 153 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1553 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 1974 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2001 | 1149 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 1998 | 244 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8634 | 0.010 |
Why?
|
| Quality of Life | 2 | 2013 | 13503 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2000 | 1153 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2005 | 1783 | 0.010 |
Why?
|
| Exercise | 1 | 2013 | 5946 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 1998 | 244 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 17135 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 2226 | 0.010 |
Why?
|
| Goiter | 1 | 1996 | 87 | 0.010 |
Why?
|
| Superior Cervical Ganglion | 1 | 1995 | 33 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 2000 | 592 | 0.010 |
Why?
|
| Anus Diseases | 1 | 1996 | 54 | 0.010 |
Why?
|
| Amyloid beta-Peptides | 1 | 2009 | 3910 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 893 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 1727 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1996 | 261 | 0.010 |
Why?
|
| Ticlopidine | 1 | 2000 | 730 | 0.010 |
Why?
|
| Peripheral Nervous System | 1 | 1996 | 151 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1996 | 422 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3587 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 1882 | 0.010 |
Why?
|
| Phosphorus | 1 | 1996 | 336 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18362 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 1996 | 142 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2001 | 2268 | 0.010 |
Why?
|
| Heart Failure | 1 | 1998 | 11858 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 556 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1998 | 1468 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7463 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 4168 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1995 | 779 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 7599 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 3813 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1999 | 2437 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1998 | 3587 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2604 | 0.010 |
Why?
|
| Vitamin E | 1 | 1996 | 874 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 3836 | 0.010 |
Why?
|
| Carbocysteine | 1 | 1991 | 1 | 0.010 |
Why?
|
| Tiopronin | 1 | 1991 | 3 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2001 | 1802 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1998 | 1804 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 1229 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 6241 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2000 | 2194 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2144 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 2087 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 2596 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12241 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1995 | 914 | 0.010 |
Why?
|
| Lung | 1 | 2008 | 10089 | 0.010 |
Why?
|
| Walking | 1 | 1996 | 1201 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2001 | 10117 | 0.000 |
Why?
|
| Homocysteine | 1 | 1991 | 637 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2006 | 13052 | 0.000 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2000 | 2763 | 0.000 |
Why?
|
| Health Education | 1 | 1994 | 1057 | 0.000 |
Why?
|
| Genotype | 1 | 2001 | 13042 | 0.000 |
Why?
|
| Calcium | 1 | 1998 | 5794 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2007 | 23631 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 1684 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1991 | 4039 | 0.000 |
Why?
|